Financial Performance - Total revenue for FY2022 reached RMB 1,237 million, representing a 42.7% increase year-over-year[7] - Adjusted net loss for FY2022 was RMB 584 million, a 112.1% increase compared to RMB 275 million in FY2021[7] - Revenue for the fiscal year ended March 31, 2022, was RMB 1,237,200, an increase of 42.7% compared to RMB 867,036 in the previous year[18] - Life Sciences Solutions revenue surged by 95.0% to RMB 359,375 from RMB 184,318 year-over-year[18] - Health Management Platform and Solutions revenue increased by 68.5% to RMB 424,941 from RMB 252,129 year-over-year[18] - The company reported an operating loss of RMB (767,398), a 69.3% increase from RMB (453,286) in the previous year[18] - The adjusted net loss was RMB (583,521), reflecting a 112.1% increase from RMB (275,079) in the previous year[18] - Revenue increased by 42.7% from RMB 867.0 million for the fiscal year ended March 31, 2021, to RMB 1,237.2 million for the fiscal year ended March 31, 2022[39] - Revenue from life sciences solutions surged by 95.0% from RMB 184.3 million to RMB 359.4 million, driven by an increase in active customers and higher average revenue per active customer[39] - Revenue from health management platforms rose by 68.5% from RMB 252.1 million to RMB 424.9 million, primarily due to increased income from insurance services and health platform solutions[39] User Growth and Market Position - Active user count increased from 5 million to 12 million during the fiscal year[7] - The market share in the overall Chinese healthcare intelligence market reached 36% in FY2022, maintaining the leading position[7] - The company holds a 25.6% market share in the emerging medical intelligence market, ranking first in revenue among medical institutions and regulatory bodies[22] - The number of top-tier research hospitals served increased from 76 to 82, and the coverage of regulatory bodies rose from 19 to 26[7] - The average revenue per customer grew by 49% year-over-year, indicating strong customer retention[7] - The hospital network expanded to over 800 hospitals, with a knowledge graph covering over 9,000 diseases[13] Innovation and Technology - The company aims to drive the intelligent transformation of the healthcare industry through continuous innovation and technology upgrades[11] - The company is focused on enhancing its core technical capabilities in deep learning, natural language processing, and secure multi-party computation[12] - The company aims to enhance its YiduCore platform to generate new insights for clinical research and accelerate the medical research process[14] - The company has developed a predictive model for fatal bacterial infections in ICUs, improving patient identification and treatment speed[15] - The company has initiated nearly 1,000 research projects and developed a real-world data clinical research platform with a contract value of several tens of millions RMB[27] - The company has developed a medical AI platform that reduces new drug development costs and shortens the average drug development cycle from 10 years to a more efficient timeline, exemplified by a rare disease drug trial that was shortened by approximately 20 months[179] Strategic Partnerships and Collaborations - The company has established partnerships with top ophthalmology hospitals in North China, East China, and South China, with a contract exceeding RMB 10 million for the NCRC construction[31] - The company has supported over 20 clinical studies and trials in collaboration with two of the three national NCRC hospitals for blood system diseases, an increase of 6 studies from the previous fiscal year[31] - The company signed a strategic agreement with a biotech firm focused on ophthalmic drug innovation, leading to a Phase III clinical trial for a specific retinal disease drug[33] - The company has established a joint research center with Tsinghua University to advance smart healthcare systems[133] Corporate Governance and Compliance - The company has complied with all relevant laws and regulations during the reporting period, with no significant violations reported[76] - The company emphasizes responsible operations and compliance policies to enhance governance and reduce operational risks[192] - The company adheres to anti-corruption laws and has implemented policies to prevent bribery, fraud, and money laundering, ensuring responsible compliance operations[196] - The company has established a remuneration committee to determine the compensation policy for directors and senior management[115] - The company has a strong commitment to business integrity and social contributions, as highlighted in its annual report[138] Environmental, Social, and Governance (ESG) Initiatives - The company aims to enhance its ESG performance by integrating sustainable development concepts into daily operations and implementing various policies and measures in the ESG field[156] - The company has established an ESG management framework to enhance sustainable development and corporate social responsibility[157] - The ESG working group is responsible for implementing and supervising ESG matters, with members from various departments including finance, legal, and human resources[161] - The company has identified 29 key ESG issues, including 9 highly important issues such as smart epidemic management and protecting customer privacy[168][169] - The company prioritizes employee training and development, ensuring a good working environment and safeguarding employee rights[169] Risk Management - The company emphasizes risk management as a crucial part of daily operations, implementing a comprehensive risk assessment management approach to ensure stable and healthy development[193] - Risk assessment involves setting objectives, identifying risks, analyzing and evaluating risks, responding to risks, and monitoring and improving risk management processes[194] - The company categorizes risks into strategic, financial, market, operational, and legal risks, assessing their impact as pure risks and opportunity risks[193] Product and Service Quality - The company has implemented strict quality control measures, achieving quality management system certification (GB/T 19001-2016/ISO9001:2015)[189] - The company has developed a comprehensive quality management system to ensure product and service quality, with no complaints received during the reporting period[191] - No cases of product recalls due to safety or health reasons were reported during the period[190] Community Engagement and Social Responsibility - Charitable donations made by the group during the reporting period were approximately RMB 19.9 million[107] - The company is committed to reducing medical resource waste and lowering new drug development costs through the application of AI and big data technologies[156] - The company aims to provide more accessible and equitable healthcare insurance services as part of its ESG strategy[168]
医渡科技(02158) - 2022 - 年度财报